MUC5AC-driven transcriptional reprogramming for stratification of pancreatic ductal adenocarcinoma by immune suppression and stromal remodeling.

4194 Background: Mucin 5AC (MUC5AC) is aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) and associated with tumor progression; however, its role in altering the tumor immune microenvironment (TIME) and immunotherapy-relevant pathways is poorly understood. Thus, we evaluated whether MUC5AC expression delineates PDAC into distinct transcriptional and immunologic subtypes based on TIME. Methods: Bulk RNA-seq data from 730 PDAC tumors (Oncology Research Information Exchange Network, ORIEN) and 360 normal pancreatic tissues (GTEx) were analyzed. Differential gene expression and pathway enrichment were assessed using Gene Ontology and KEGG analyses. Immune infiltration and stromal states were inferred using multiple complementary deconvolution algorithms (CIBERSORT and xCell). Tumors in the lowest quartile of MUC5AC expression (≤25th percentile; MUC5AC-low, MUC5AC-L) were compared with the remaining samples (MUC5AC-high, MUC5AC-H). Associations between MUC5AC expression and immune cell populations and immunomodulatory genes were evaluated by using correlations and group-based analyses with false discovery rate (FDR) corrections. Results: Principal component analysis demonstrated clear separation between PDAC tumors and normal pancreas and revealed distinct transcriptional programs between MUC5AC-H (N = 544) and MUC5AC-L (N = 186) tumors. MUC5AC-H tumors exhibited a profoundly immunosuppressive and stromal-remodeled TIME, including enrichment of M2 macrophages, regulatory T cells, activated natural killer ells, fibroblast-associated signatures, and significantly higher immune and stromal scores (multiple FDR ≤10⁻⁶ to ≤10⁻²⁸). In contrast, MUC5AC-L tumors showed relatively enrichment of immune-activating populations, including naïve B cells, dendritic cell subsets, resting CD4⁺ memory T cells, and CD8⁺ T cells (multiple FDR < 10⁻¹⁵). MUC5AC expression strongly correlated with immune checkpoint genes CD274 (PD-L1) and TIGIT , and with multiple suppressive immune populations (p < 0.01 to < 10⁻¹⁰). Conclusions: MUC5AC defines a transcriptionally distinct, immunosuppressive PDAC subtype characterized by stromal activation, macrophage/Treg enrichment, and immune checkpoint engagement. MUC5AC may serve as a biomarker for immune stratification and supports rational combination strategies integrating stromal targeting with immune checkpoint modulation in PDAC.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-27
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.4194
Primary Topic
Glycosylation and Glycoproteins Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MUC5AC-driven transcriptional reprogramming for stratification of pancreatic ductal adenocarcinoma by immune suppression and stromal remodeling.

Michael J. Cavnar, Robert J. Rounbehler, Tiago Biachi De Castria, Midhun Malla et al.
Journal of Clinical Oncology
Glycosylation and Glycoproteins Research
article

MUC5AC-driven transcriptional reprogramming for stratification of pancreatic ductal adenocarcinoma by immune suppression and stromal remodeling.

Michael J. Cavnar, Robert J. Rounbehler, Tiago Biachi De Castria, Midhun Malla, Carlos H.F. Chan, Michelle L. Churchman, Vaibhav Sahai, Michele M. Gage, Yongchen Guo, Muneeb Rehman, Hassan Hatoum, Melissa Fishel, Bodour Salhia, Christos Fountzilas, Yonghua Laura Bao, Wancai Yang, Emily Baiyee Toegel, Upender Manne, Patrick M. Boland, Ashish Manne
article en

Abstract

4194 Background: Mucin 5AC (MUC5AC) is aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) and associated with tumor progression; however, its role in altering the tumor immune microenvironment (TIME) and immunotherapy-relevant pathways is poorly understood. Thus, we evaluated whether MUC5AC expression delineates PDAC into distinct transcriptional and immunologic subtypes based on TIME. Methods: Bulk RNA-seq data from 730 PDAC tumors (Oncology Research Information Exchange Network, ORIEN) and 360 normal pancreatic tissues (GTEx) were analyzed. Differential gene expression and pathway enrichment were assessed using Gene Ontology and KEGG analyses. Immune infiltration and stromal states were inferred using multiple complementary deconvolution algorithms (CIBERSORT and xCell). Tumors in the lowest quartile of MUC5AC expression (≤25th percentile; MUC5AC-low, MUC5AC-L) were compared with the remaining samples (MUC5AC-high, MUC5AC-H). Associations between MUC5AC expression and immune cell populations and immunomodulatory genes were evaluated by using correlations and group-based analyses with false discovery rate (FDR) corrections. Results: Principal component analysis demonstrated clear separation between PDAC tumors and normal pancreas and revealed distinct transcriptional programs between MUC5AC-H (N = 544) and MUC5AC-L (N = 186) tumors. MUC5AC-H tumors exhibited a profoundly immunosuppressive and stromal-remodeled TIME, including enrichment of M2 macrophages, regulatory T cells, activated natural killer ells, fibroblast-associated signatures, and significantly higher immune and stromal scores (multiple FDR ≤10⁻⁶ to ≤10⁻²⁸). In contrast, MUC5AC-L tumors showed relatively enrichment of immune-activating populations, including naïve B cells, dendritic cell subsets, resting CD4⁺ memory T cells, and CD8⁺ T cells (multiple FDR < 10⁻¹⁵). MUC5AC expression strongly correlated with immune checkpoint genes CD274 (PD-L1) and TIGIT , and with multiple suppressive immune populations (p < 0.01 to < 10⁻¹⁰). Conclusions: MUC5AC defines a transcriptionally distinct, immunosuppressive PDAC subtype characterized by stromal activation, macrophage/Treg enrichment, and immune checkpoint engagement. MUC5AC may serve as a biomarker for immune stratification and supports rational combination strategies integrating stromal targeting with immune checkpoint modulation in PDAC.

Journal of Clinical OncologyVol. 44(16_suppl)
Rutgers, The State University of New Jersey (US), University of Southern California (US), Indiana University Health (US), University of Kentucky HealthCare (US), Roswell Park Comprehensive Cancer Center (US), University of Michigan (US), Walter Reed National Military Medical Center (US), University of Iowa Hospitals and Clinics (US), Moffitt Cancer Center (US), University of Alabama at Birmingham (US), Indiana Cancer Consortium (US), University of Colorado Cancer Center (US), Rutgers Cancer Institute (US), University of Oklahoma Health Sciences Center (US), University of Virginia (US), The Ohio State University (US), Indiana University – Purdue University Indianapolis (US), University of Colorado Denver (US)
Good health and well-being
Openalex Percentile: Top 9%
Glycosylation and Glycoproteins Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.